AHRR fusion-negative tumors diagnosed as angiofibroma of soft tissue are genetically heterogeneous and differ clinicopathologically from AHRR-rearranged tumors
Virchows Archiv · 30.10.2026
DOI: 10.1007/s00428-026-04752-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Virchows Archiv, online erschienen am 30.10.2026. Verfasst von Felix Keil und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Pathology of the University Regensburg, Regensburg, Germany. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
Angiofibroma of soft tissue (AFST) is a benign mesenchymal tumor type driven by AHRR :: NCOA2 in 60–80% of cases, leading to aryl hydrocarbon receptor (AHR) pathway-activation and cytochrome P450 1A1 (CYP1A1) overexpression (“AHR-activated” AFST). The remaining 30% are incompletely characterized. Here, we studied 16 tumors diagnosed prospectively as AFST but lacking CYP1A1 expression by immunohistochemistry (IHC), which occurred in 8 males and 8 females (median age: 42.5 yr; range: 5–63 yr). Tumor sites were lower extremity (6 patients), upper extremity (4), trunk (3), nose (1), vulva (1) and esophagus (1). Tumors exhibited subtle differences compared to AHR-activated AFSTs, including less uniform vessels and more frequent fascicular and infiltrative growth. Fluorescence in situ hybridization (FISH) was negative for AHRR rearrangement in all 12 tested cases. Sequencing demonstrated inactivating tumor suppressor mutations (6 NF1 , 2 each with PTCH1 and TP53 ; 1 FAT1 ; 1 PTEN and CDKN2A / B ; 1 STK11 ) in 9 of 16 tumors. One tumor harbored EWSR1::GFI1B . Clinical follow-up was available for 9 patients (56%, median 3.5 yr, range: 1 mo–5.6 yr). The EWSR1 :: GFI1B -fusion AFST did not recur, consistent with prior reports. Pooling study and literature cases demonstrated higher local recurrence in AHRR / EWSR1 -fusion-negative AFST (4/11; 36%) compared to AHR-activated AFST (1/27; 4%) (Kaplan–Meier log-rank p = 0.0011), as well as different age and body site distributions. We conclude that tumors diagnosed as AFST but lacking AHRR fusions are genetically heterogeneous and clinicopathologically different from AHR-activated AFST. Tumors lacking AHRR fusion potentially should not be co-classified with AHRR -rearranged AFST.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute for Pathology of the University Regensburg, Regensburg, Germany.
- Department of Pathology and Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
- Department of Clinical Genetics, Pathology, and Molecular Diagnostics, Division of Laboratory Medicine, Lund, Sweden.
- Department of Pathology, Brigham and Women's Hospital, and Harvard Medical School, 75 Francis St., Boston, MA 02115, USA.
- Department of Pathology, Brigham and Women's Hospital, and Harvard Medical School, 75 Francis St., Boston, MA 02115, USA. dpapke@bwh.harvard.edu.
Zitieren
APA
Keil, F., Odintsov, I., Siegmund, S., Magnusson, L., Bauer, A. H., Hirsch, D., Evert, M., Mertens, F., Hornick, J. L., Fletcher, C. D. M., & Papke, D. J. (2026). AHRR fusion-negative tumors diagnosed as angiofibroma of soft tissue are genetically heterogeneous and differ clinicopathologically from AHRR-rearranged tumors. Virchows Archiv. https://doi.org/10.1007/s00428-026-04752-3
Vancouver
Keil F, Odintsov I, Siegmund S, Magnusson L, Bauer AH, Hirsch D, et al. AHRR fusion-negative tumors diagnosed as angiofibroma of soft tissue are genetically heterogeneous and differ clinicopathologically from AHRR-rearranged tumors. Virchows Archiv. 2026. doi:10.1007/s00428-026-04752-3
BibTeX
@article{Keil2026,
author = {Keil, Felix and Odintsov, Igor and Siegmund, Stephanie and Magnusson, Linda and Bauer, Anna H and Hirsch, Daniela and Evert, Matthias and Mertens, Fredrik and Hornick, Jason L and Fletcher, Christopher D M and Papke, David J},
title = {AHRR fusion-negative tumors diagnosed as angiofibroma of soft tissue are genetically heterogeneous and differ clinicopathologically from AHRR-rearranged tumors},
journal = {Virchows Archiv},
year = {2026},
doi = {10.1007/s00428-026-04752-3}
}
EUVIMED